title: Is chemotherapy-induced neutropenia a prognostic factor in patients with ovarian cancer?
abstract: OBJECTIVE
  This study sought to determine if relative neutropenia (RN) following six cycles of paclitaxel/carboplatin could serve as a prognostic factor in patients with ovarian cancer.
  
  
  METHODS
  A single institution, retrospective study.
  
  
  METHODS
  Tertiary academic referral center, Seoul, Korea Population. A total of 179 patients who underwent primary cytoreductive surgery, followed by six cycles of paclitaxel/carboplatin chemotherapy to treat epithelial ovarian cancer.
  
  
  METHODS
  Relative neutropenia was defined by an absolute neutrophil count < 1000 neutrophils/mm(3) at chemotherapy cycle nadir. To eliminate the effects of dose reduction (DR) and schedule delay (SD) on the outcome of analysis, 49 patients who had this were excluded, and a subset analysis of 130 patients who received standard doses and schedules of chemotherapy was performed.
  
  
  METHODS
  Progression free and overall survival.
  
  
  RESULTS
  The median progression free survival (PFSs) of neutropenic and non-neutropenic patients was 34 and 22 months, respectively; the median overall survival (OS) times were 67 and 56 months, respectively, with no significant differences in PFS and OS (p = 0.26, 0.59). Multivariate analysis revealed that stage, clear cell histology, and > or =1 cm residual tumor mass were independent prognostic predictors, while RN was not. In the subset analysis confined to the patients without DR and SD, the results were not changed.
  
  
  CONCLUSIONS
  Chemotherapy-induced neutropenia was not a significant prognostic indicator in ovarian cancer patients treated with paclitaxel/carboplatin as first-line chemotherapy.
authors.affiliation: Department of Obstetrics and Gynecology, University of Ulsan, College of Medicine, Asan Medical Center, Asanbyeongwongil 86, Songpa-gu, Seoul, Korea.
authors.forename: Jae-Joon
authors.initials: JJ
authors.lastname: Kim
authors.forename: Jeong-Yeol
authors.initials: JY
authors.lastname: Park
authors.forename: Dae-Yeon
authors.initials: DY
authors.lastname: Kim
authors.forename: Jong-Hyeok
authors.initials: JH
authors.lastname: Kim
authors.forename: Yong-Man
authors.initials: YM
authors.lastname: Kim
authors.forename: Joo-Hyun
authors.initials: JH
authors.lastname: Nam
authors.forename: Young-Tak
authors.initials: YT
authors.lastname: Kim
mesh_terms: D000046:Academic Medical Centers; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects*; D015331:Cohort Studies; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D007723:Korea; D007958:Leukocyte Count; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D009503:Neutropenia / Q000139:chemically induced* / Q000401:mortality; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D011237:Predictive Value of Tests; D011379:Prognosis; D012189:Retrospective Studies; D012720:Severity of Illness Index; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D016190:Carboplatin; D017239:Paclitaxel